Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30873486 | 1.00 | LMNA (0.31) | LMNAMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL30873472 | 1.00 | LMNA (0.31) | LMNAMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL30873384 | 0.88 | ERAP1 (0.31) | — | |
| SCHEMBL29322143 | 0.88 | ERAP1 (0.31) | — | |
| SCHEMBL29321862 | 0.88 | LMNA (0.35) | LMNAMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL30873444 | 0.88 | LMNA (0.35) | LMNAMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL31527412 | 0.88 | LMNA (0.35) | LMNAMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL31527354 | 0.85 | LMNA (0.31) | LMNAMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL29322144 | 0.81 | KRAS (0.43) | — | |
| SCHEMBL30873479 | 0.81 | LMNA (0.34) | LMNAMEN1KMT2ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | AZI2, HDAC5, HDAC4 | LMNA 4375/4885MEN1 3341/4885KMT2A 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.